Myriad Genetics, Inc. · NASDAQ:MYGN
Myriad Genetics — Q2 FY2021 Earnings Presentation
19 slides from Myriad Genetics's earnings presentation, Feb 23, 2021
Slide 1: Myriad Genetics December 2020 Quarterly Earnings
Myriad Genetics December 2020 Quarterly Earnings February 23, 2021
Slide 2: Forward looking statements
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com 2 Forward looking statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based
Slide 3: Fulfilling our mission, executing our strategy
3 Paul J. Diaz President and CEO FULFILLING OUR MISSION, EXECUTING OUR STRATEGY In the most challenging environment any of us has ever seen, we continue to fulfil our mission to advance the health and wellbeing of our patients by empowering them and healthcare providers with life-changing genetic in
Slide 4: Key quarterly highlights
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com 4 Key quarterly highlights • Dec 2020 quarter revenue of $154.6 million up 6% sequentially • 7% sequential test volume growth despite COVID-19 related headwinds • Pricing stable with sequential improvements in GeneSight and prenatal ASP
Slide 5: Executing on our four-point strategic roadmap
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Executing on our four-point strategic roadmap • Explore opportunities to invest in new products, innovations and technologies • Direct-to-consumer marketing models • Partnerships with payers, health systems, and other healthcare provide
Slide 6: Transformation phases and objectives
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com H2 2020 BUILD CULTURE OF SERVICE EXCELLENCE, PRIORITIZE INNOVATION, REDUCE COMPLEXITY 2021 2022 PHASE I: RESET THE BASE • Reorganize around strategic priorities, reduce complexity and cost • Improve financial performance and transparenc
Slide 7: Meeting patient and customer needs
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Meeting patient and customer needs 7 Mission Potential Catalysts • Improving prenatal economics • Digital marketing and customer experience • Primary care expansion • Pricing/reimbursement strategy • Telehealth partnerships • Somatic st
Slide 8: Tech and health leaders – current and new
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Chris Williamson SVP, Information Systems and Security Maggie Ancona SVP, Enterprise Transformation and Program Management Jackie Zou VP, Business Development Edward Gala SVP, Enterprise Marketing Communications David Hammer SVP, Revenu
Slide 9: Energage Top Places to Work List
©2019 Myriad Genetics, Inc. All rights reserved.. www.Myriad.com 9 Energage Top Places to Work List • No.1 in health industry
Slide 10: December 2020 Quarterly Earnings – Bryan Riggsbee, CFO
Myriad Genetics December 2020 Quarterly Earnings Bryan Riggsbee, CFO February 23, 2021 10
Slide 11: December 2020 Quarter – increased volume, stable pricing
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com December 2020 Quarter – increased volume, stable pricing 11 HEREDITARY CANCER PRENATAL MENTAL HEALTH SEQ. CHANGE SEP. 2020-DEC. 2020 OVERALL COMPANY -2% +28% +51% +6% +6% +7% +13% +7% -8%* +20% +34% -1% REVENUE TEST VOLUME ASP MIX DRIVE
Slide 12: Improving financial trends
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Improving financial trends 12 REVENUE SEQUENTIAL GROWTH ADJUSTED OP INCOME ADJUSTED GROSS MARGIN $154.6 SEQUENTIAL INCREASE SEQUENTIAL INCREASE $145.2$93.2 JUN 2020 SEP 2020 DEC 2020 70.1%69.8%60.9% ($42.3) ($11.3) ($11.3) +0.0 54% 6% S
Slide 13: December 2020 Quarter - revenue by product
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com December 2020 Quarter - revenue by product WH = Women’s Health ONC = Oncology MH = Mental Health AI = Autoimmune 13 (In millions) % Change Hereditary Cancer Testing $ 35.2 $ 43.5 $ — $ — $ — $ $ 67.1 $ 50.6 $ — $ — $ — $ 117.7 -33.1% Pr
Slide 14: December 2020 Quarter - income statement
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com December 2020 Quarter - income statement Myriad Genetics Income Statement GAAP Results Adjusted Results (in millions, except share data) Fiscal Year Ends Jun. 30 Dec-20 Dec-20 Total Revenues $154.6 $154.6 Cost of Goods Sold 47.2 46.3 Gr
Slide 15: Elevating prenatal product potential, best-in-class results
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com 15 Elevating prenatal product potential, best-in-class results 15 Sensitivity for 5 common microdeletions Specificity for 5 common microdeletions 97.2% 99.8% Prequel with AMPLIFY™ increases accuracy 10X Alpha Thalassemia enhancements re
Slide 16: Elevating product potential, commercial progress
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com 16 Elevating product potential, commercial progress 16 • Japan CDx revenue +167% • myChoice CDx reimbursement starting Jan. 1, 2021 • Recent approvals of BRACAnalysis CDx in pancreatic and prostate cancer • New Medicare LCD in non- favo
Slide 17: Advantage of combinatorial pharmacogenomics
Advantage of combinatorial pharmacogenomics Outcome F-Statistic or χ2 P-Value F-Statistic or χ2 P-Value Symptom Improvement 9.3 0.002 0.02 0.883 Response 4.4 0.036 0.02 0.892 Remission 5 0.025 0.06 0.802 Symptom Improvement 7.7 0.006 0.1 0.754 Response 4 0.046 0.13 0.718 Remission 4.1 0.043 0.03 0.8
Slide 18: Unlocking the power of genetics to improve and transform lives
18 Unlocking the power of genetics to improve and transform lives
Slide 19: ery yriad.
Ee . {ne La ery yriad. fi) WHEN DECISIONS MATTER